Francesco Claps
@FraClaps
MD, PhD candidate @UniLeiden | Consultant Urological Surgeon @iov_irccs | Fellow @NKI_nl | Former fellow Fundaciòn IVO | @SIU_Italia Communications Office
You might like
📣 Corso di Perfezionamento UNIPA: “Diagnostica e Procedure Urologiche Guidate da Imaging” 🗓️ Marzo–Novembre 2026 | 400 ore | 16 CFU Focus su imaging in urologia (eco, TC, RM mp, PET/CT) + procedure guidate. ⏳ Scadenza: 03/02/2026 Info: [email protected]
🎆📢First of 2026! Should we really give MMC maintenance in intermediate-risk #NMIBC, and for how long? #EAU guidelines recommend adj chemo but the optimal schedule remains unclear We tried to answer this clinically relevant gap.👇🧵 @Uroweb @urotoday @oncodaily @SpringerNature
Pleased to publish #CostEffectiveness data #LATPvsTRUS in @EurUrolFocus THM: •average cost TRUS=£917; LATP=£1062 (∵ device cost/takes longer) •#LATP not cost-effective (QALY) But... •only 4m f/u so doesnt account for ⬆️ PCa diag #TRANSLATE_Trial eu-focus.europeanurology.com/article/S2405-…
Need an update on the molecular pathology of bladder cancer? I am delighted to share a comprehensive review article by Dr. Antonio Lopez-Beltran and colleagues, published in the 2026 Annual Review Issue of Histopathology @Histo_Journal @daniel_berney 🔗 Article:…
#mdpijcm 🩺#HighlyCitedPaper Citations 29🙌 The Prognostic Significance of Histological Subtypes in Patients with 𝐌𝐮𝐬𝐜𝐥𝐞-𝐈𝐧𝐯𝐚𝐬𝐢𝐯𝐞 𝐁𝐥𝐚𝐝𝐝𝐞𝐫 𝐂𝐚𝐧𝐜𝐞𝐫 👉mdpi.com/2885444 👥@GGiannarini @AlessiaCim @Nicp85Pavan @ongarluc_1991 @FraClaps @MediPharma_MDPI
BCG-unresponsive NMIBC trials feel confusing—and inconsistent EFS reporting is a big reason why We analyze the CIS+ cohorts of 4-FDA registration trials to provide interpretable EFS estimates 🧵👇 @Annals_Oncology @tompowles1 @JoshMeeks @wandering_gu doi.org/10.1016/j.anno…
“Low-grade Non–Muscle-Invasive Bladder Cancer: Molecular Landscape, Treatment Strategies, and Emerging Therapies” - just published in Nature Reviews Urology @NatRevUrol. This State-of-the-Art review by Drs. Roger Li @UrogerliMD, Lexi Wen, and colleagues @philippespiess…
Great brainstorming session today at #EMUC25 focused on advancing the most current insights in urothelial carcinoma research 🚀
One slide says it all! Terrific distillation by @MichvdHeijden of what to do in emerging pt populations in #bladdercancer, namely pts who received perioperative IO. Mirrors discussions we have been having in #kidneycancer. #ESMO25
⚡️ Cost-effectiveness of treatments for BCG-unresponsive CIS - analysis from our multicenter IBCG team. Five strategies modeled: 🔹Radical cystectomy (RC) 🔹Pembrolizumab 🔹Nadofaragene firadenovec 🔹Nogapendekin (NAI-BCG) 🔹Gemcitabine + Docetaxel ➡️Comprehensive…
In a trial of men with suspected prostate cancer, biparametric MRI, which excludes the gadolinium contrast sequence, was noninferior to multiparametric MRI for detecting clinically significant cases. 🧵 ja.ma/4nhCVqy
On September 9, 2025, the Food and Drug Administration approved gemcitabine intravesical system (Inlexzo, Janssen Biotech, Inc.) for adults with BCG - unresponsive NMIBC with CIS with or without papillary tumors. Also known as TAR-200: this gemcitabine intravesical system is…
JUST IN: IMvigor011 in muscle-invasive bladder cancer (MIBC) hits both DFS & OS with PD-L1 inhibitor Atezolizumab in ctDNA+ population. Major news for Precision Oncology in adjuvant Solid Cancers! @NateraGenetics @tompowles1 @Roche natera.com/company/news/i…
The Prostate Imaging for Recurrence Reporting (PI-RR) system standardizes MRI performance and interpretation after prostatectomy or radiation therapy and is an essential reference for radiologists in standardizing reporting of recurrent prostate cancer. bit.ly/3JdTjtG
Confirmation of the results of our RCT showing that PLND reduces metastasis without affecting BCR. @UrologyMSK @Uroweb @EUplatinum @JUrology @VickersBiostats #prostatecancer
Our team is in Sevilla for #UROonco25 📩 #NMIBC Deintensify LG Biomarkers to ⬇️ cystoscopy in HG #MIBC ctDNA is the future #UTUC Tailored patient care Go for kidney-sparing treatment @Uroweb @EAU_Uroonco @EAUYAUrology
Excellent comprehensive review + metaanalysis on the diagnostic role of #PSMA Pet in #ProstateCancer ✅ High diagnostic value of PSMA PET, especially when combined with #MRI ✅ NPV indicates limitations to guide LND - not enough to omit biopsy @EUplatinum @oncodaily @elio_mazzone
🚨New in @EUPlatinum! 📌 PSMA PET for Prostate Cancer Diagnosis & Staging by @elio_mazzone et al 🧠 This comprehensive meta-analysis confirms the high diagnostic value of PSMA PET—especially when combined with MRI—but reminds us it’s not enough to skip biopsy or lymph node…
A 🧵 on our recent study on surveillance for IR-NMIBC @EurUrolOncol authors.elsevier.com/c/1l7pU_wtP00L… There is limited evidence on follow-up for IR-NMIBC. We used data from >2000 primary Ta–T1 NMIBC to stratify IR-NMIBC by recurrence risk and propose a risk-adapted follow-up approach.
United States Trends
- 1. Porzingis N/A
- 2. Kuminga N/A
- 3. Warriors N/A
- 4. Skubal N/A
- 5. Gonzaga N/A
- 6. Podz N/A
- 7. Hield N/A
- 8. #AEWDynamite N/A
- 9. Dalen Terry N/A
- 10. Ty Jerome N/A
- 11. Yabu N/A
- 12. Jokic N/A
- 13. Knicks N/A
- 14. Tigers N/A
- 15. Trey Murphy N/A
- 16. Doug Christie N/A
- 17. Brandon Garrison N/A
- 18. POTS N/A
- 19. Tingus Pingus N/A
- 20. Zags N/A
You might like
-
Carlo Trombetta
@Trombetta_Carl -
Nicola Pavan
@Nicp85Pavan -
Dept. of Urology | University of Trieste
@UrologiaTrieste -
Francesco, Del Giudice
@f_delgiudice -
Daniele Amparore
@danieleamparore -
Il mago di Floz
@ilmagodifloz -
Maurizio Neri
@maurizioneri79 -
Giovanni Liguori
@gioliguori33 -
alcafar
@alcafar76 -
Luca Ongaro
@ongarluc_1991 -
Andre Ventuno
@andr3_21 -
Mauro Fodaroni
@maurofodaroni -
Mimmo Caporali
@MimmoCaporali -
Soppressatira
@Soppressatira -
Stefano Belli
@Mordicchio90
Something went wrong.
Something went wrong.